435 related articles for article (PubMed ID: 8894198)
1. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
Zohar J; Judge R
Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
[TBL] [Abstract][Full Text] [Related]
2. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
3. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Albert U; Aguglia E; Maina G; Bogetto F
J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
[TBL] [Abstract][Full Text] [Related]
5. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
6. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
Braconnier A; Le Coent R; Cohen D;
J Am Acad Child Adolesc Psychiatry; 2003 Jan; 42(1):22-9. PubMed ID: 12500073
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
9. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
10. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
[TBL] [Abstract][Full Text] [Related]
11. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
13. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators.
Lecrubier Y; Bakker A; Dunbar G; Judge R
Acta Psychiatr Scand; 1997 Feb; 95(2):145-52. PubMed ID: 9065680
[TBL] [Abstract][Full Text] [Related]
14. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
[TBL] [Abstract][Full Text] [Related]
15. Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.
Ulloa RE; Nicolini H; Avila M; Fernández-Guasti A
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):85-96. PubMed ID: 17343556
[TBL] [Abstract][Full Text] [Related]
16. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
17. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
[TBL] [Abstract][Full Text] [Related]
18. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
Dannon PN; Sasson Y; Hirschmann S; Iancu I; Grunhaus LJ; Zohar J
Eur Neuropsychopharmacol; 2000 May; 10(3):165-9. PubMed ID: 10793318
[TBL] [Abstract][Full Text] [Related]
19. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.
Lecrubier Y; Judge R
Acta Psychiatr Scand; 1997 Feb; 95(2):153-60. PubMed ID: 9065681
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
